DYN

Equibles Rating blended score · not investment advice

Overall

Neutral

Technical · trend & momentum Strong Buy

◦ 50 / 200-day cross no cross

+ Price vs 200-day avg +26% above

+ Price vs 50-day avg +22% above

◦ RSI (14) 69 · neutral

+ MACD trend positive

+ 52-week position 87% · near high

Sentiment · smart money Bearish

◦ Trend (MA cross) 50d $19 › 200d $18 — 50d above 200d

◦ Institutional flow 2 of 228 funds reported for Jun 30 · net 0 sh shares

− Insider flow Net -$38.8M over 90 days · 86% sells

− Short interest 15.97% of float · ▲ +2.4% MoM · 14.3 days cover

◦ Volume signal Volume near normal

+ Institution breadth 228 holders — near 3-yr high, broad support

Fundamentals Weak

− EPS growth −3% Y/Y

− Free cash flow $-405.1M

+ Balance sheet net cash $744.4M

Blended from price, positioning & fundamentals · daily-close · not investment advice.

Up next

Next earnings call

Aug 10, 2026 Est · unconfirmed · in 5 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed May 11, 2026

Technicals

trend & momentum for long-term holders Strong Buy

0 · 2 · 4

50 / 200-day cross

no cross Neutral

Price vs 200-day avg

+26% above Bullish

Price vs 50-day avg

+22% above Bullish

RSI (14)

69 · neutral Neutral

MACD trend

positive Bullish

52-week position

87% · near high Bullish

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $19 › 200d $18 — 50d above 200d

Institutional flow Flat

2 of 228 funds reported for Jun 30 · net 0 sh shares

Insider flow Distributing

Net -$38.8M over 90 days · 86% sells

Short interest Rising

15.97% of float · ▲ +2.4% MoM · 14.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

228 holders — near 3-yr high, broad support

Price context

position in its 52-week range

52-wk low $8 Now $23 · 87% 52-wk high $25

vs 200-day avg +26% vs 50-day avg +22%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
DYN Dyne Therapeutics, Inc. this stock	$3.26B	+16.8%	—	—	16.0%
AKTX Akari Therapeutics Plc	$998.08B	-5.7%	—	—	0.0%
ONC BeOne Medicines Ltd.	$488.96B	+1.9%	+22179.2%	995.1	0.1%
VRTX Vertex Pharmaceuticals Inc / Ma	$134.41B	+16.8%	+46.2%	31.4	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$69.33B	-15.7%	+20.8%	16.1	3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders

Holders

228

% held: 128.8%
Reported: 2 of 228
Top holder: T. Rowe Price Investment…

Held Float

View

Held by Funds

Fund positions

233

View

Short & Settlement

Short Interest Rising

Shares short

22.8M

Days to cover: 14.3d
Change: +536.8K sh

View

Short Volume

Short vol %

85%

As of: Jul 6, 2026

Short Total

View

Fails to Deliver

FTD shares

2.8K

Value: $50.8K
As of: Jun 12, 2026

View

Off-Exchange

Off-exchange %

38.3%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$38.8M

Buyers / Sellers: 1 / 6

Buyers Sellers

View

Financials

Net income (FY)

$-446.2M

EPS diluted: $-3.47

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 11

View

Proposed Sales

Value

$48.1K

Shares: 2.4K
Filed: Jun 25, 2026

View

Exempt Offerings

Offering

$115.7M

Filed: Aug 14, 2020

View

Earnings & Events

Earnings Calls

Last call

Jun 3, 2026

View

Performance

	5D	20D	120D	MTD	YTD
DYN	+9.1%	+24.1%	+28.5%	+2.8%	+16.8%
SPY	+3.1%	-0.8%	+8.2%	+0.6%	+10.2%
vs SPY	+6.0%	+24.8%	+20.3%	+2.2%	+6.6%

Price & Indicators

Technicals

Versus peers

At a glance

Performance